Opportunity Information: Apply for PAR 14 241
Apply for PAR 14 241
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Research Projects to Enhance Applicability of Mouse Models for Translational Research (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research 93.396 Cancer Biology Research.
- This funding opportunity was created on May 30, 2014 and posted on May 30, 2014.
- Applicants must submit their applications by May 7, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $450,000.00 in funding.
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments Public housing authorities/Indian housing authorities For profit organizations other than small businesses Small businesses Native American tribal governments (Federally recognized) Special district governments Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments County governments Private institutions of higher education Independent school districts Native American tribal organizations (other than Federally recognized tribal governments).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This NIH/NCI grant opportunity (PAR-14-241) is an R01 research project funding announcement focused on making mouse cancer and tumor models more trustworthy and more directly useful for translational cancer research, meaning research that is intended to inform clinical decisions and ultimately benefit patients. While the National Cancer Institute has long funded many mechanistic, hypothesis-driven R01 studies that use mice or develop mouse cancer models (including human tumor xenografts or other "human-in-mouse" approaches), this FOA was created to target a different bottleneck: the gap between using mouse models as convenient experimental systems and demonstrating that a given model is actually appropriate, reliable, and informative for a specific translational question. The central theme is improving confidence that results obtained in mouse systems meaningfully map onto human cancer biology and treatment response, and doing so in ways that the broader research community can adopt.
Projects proposed under this FOA are expected to address limitations that commonly reduce the translational value of mouse oncology models. That can include identifying and correcting model artifacts, improving how models are designed to better reflect human disease, and clarifying when a model is or is not fit for a particular purpose. The announcement emphasizes several examples of the kinds of work NCI is looking for: studies that overcome known shortcomings in mouse models or human-in-mouse tumor models; efforts that define new translational uses for mouse models or mouse genetics where there are unmet needs; development of improved standards and best practices for building and using mouse cancer models; and the creation of rigorous approaches for validating, credentialing, or benchmarking models so their strengths and limitations are transparent. It also highlights interest in broadly applicable tools or resources, such as tool strains, reference resources, or methods that enable stronger cross-species comparisons between mouse and human cancers. In practical terms, this FOA is aiming to move the field beyond one-off model building and toward reproducible, well-characterized modeling approaches that can be trusted when informing decisions about targets, biomarkers, or therapeutic strategies.
Administratively, this is a discretionary grant mechanism using the NIH R01 funding instrument, administered by the National Institutes of Health with cancer-related activities aligned to CFDA program areas 93.393, 93.394, 93.395, and 93.396 (spanning cancer cause and prevention, detection and diagnosis, treatment, and cancer biology). The listed award ceiling is $450,000 (as provided in the source data). No cost sharing or matching is required. The opportunity was posted May 30, 2014, with an original and final closing date of May 7, 2017, and it was archived June 7, 2017, meaning it is no longer active but remains important as a statement of NCI priorities during that period and as a useful reference for the types of mouse model rigor and translational alignment NCI has sought to encourage.
Eligibility is broad and includes many categories of U.S.-based organizations such as public and private institutions of higher education, nonprofits (including 501(c)(3) and certain non-501(c)(3) entities), for-profit organizations (including small businesses and other for-profits), and various levels of government (state, local, tribal, special districts, and housing authorities). The FOA also explicitly includes a wide range of institution types and communities, including HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and AANAPISI organizations, as well as faith-based and community-based organizations. Foreign participation is allowed: non-U.S. entities (foreign organizations and foreign institutions) are eligible to apply, non-U.S. components of U.S. organizations are eligible, and foreign components as defined by NIH policy are permitted. For applicants, the practical takeaway is that NCI intended this to be accessible to a wide ecosystem of researchers and institutions capable of improving model relevance, standardization, and validation for translational cancer research.
The full archived announcement and official details were provided via the NIH Grants Guide page at http://grants.nih.gov/grants/guide/pa-files/PAR-14-241.html, and technical access questions were directed to the NIH Office of Extramural Research (OER) webmaster email listed in the source.
FAQs: NIH/NCI PAR-14-241 (R01) - Improving the Translational Relevance of Mouse Cancer Models
What is PAR-14-241?
PAR-14-241 is an NIH/NCI Program Announcement for an R01 Research Project Grant focused on improving how trustworthy and translationally useful mouse cancer and tumor models are for cancer research that aims to inform clinical decisions and benefit patients.
What is the main goal of this funding opportunity?
The central goal is to close the gap between using mouse models as convenient experimental systems and proving that a particular mouse model is appropriate, reliable, and informative for a specific translational cancer research question. The emphasis is on increasing confidence that findings in mouse systems meaningfully map onto human cancer biology and treatment response in ways the broader research community can adopt.
What kinds of problems in mouse oncology models does this FOA aim to address?
Projects are expected to address limitations that reduce translational value, such as model artifacts, design issues that make a model poorly reflect human disease, and uncertainty about whether a model is fit for a particular purpose. The FOA is interested in work that clarifies when a model should or should not be used for a given translational question.
Is this FOA meant for basic mechanistic mouse studies?
It is distinct from traditional mechanistic, hypothesis-driven R01 studies that simply use mice or develop mouse cancer models. This FOA targets a different bottleneck: demonstrating appropriateness, reliability, and translational relevance of models for specific translational uses, rather than only building or using models in one-off ways.
What types of projects does NCI highlight as examples under PAR-14-241?
The announcement highlights examples including: overcoming known shortcomings in mouse models or human-in-mouse tumor models; defining new translational uses for mouse models or mouse genetics where needs are unmet; developing improved standards and best practices for building and using mouse cancer models; and creating rigorous approaches for validating, credentialing, or benchmarking models so strengths and limitations are transparent.
Does this opportunity include human tumor xenografts and other "human-in-mouse" approaches?
Yes. The FOA explicitly references mouse cancer models including human tumor xenografts and other "human-in-mouse" tumor model approaches, particularly where the work improves shortcomings and strengthens translational relevance.
What does "translational cancer research" mean in the context of this FOA?
Here, translational cancer research refers to research intended to inform clinical decisions and ultimately benefit patients. The FOA focuses on ensuring that mouse model results can be relied upon to reflect human cancer biology and treatment response for translational questions.
What does the FOA mean by making models more "trustworthy"?
Trustworthiness refers to improving confidence that a model is reliable and appropriate for its intended translational use. This includes identifying and correcting artifacts, improving model design to better reflect human disease, and providing rigorous validation or benchmarking so limitations and strengths are clearly understood.
What is meant by validating, credentialing, or benchmarking mouse models?
These terms refer to rigorous approaches that evaluate and document how well a mouse model matches human cancer biology or treatment response for a defined purpose. The goal is to make performance and limitations transparent and reproducible for the broader community.
Does the FOA prioritize community-adoptable standards and resources?
Yes. A key theme is moving beyond one-off model building toward reproducible, well-characterized modeling approaches that the broader research community can adopt, including improved standards, best practices, and broadly applicable tools or resources.
What kinds of tools or resources are mentioned as being of interest?
The FOA highlights interest in broadly applicable tools or resources such as tool strains, reference resources, or methods that enable stronger cross-species comparisons between mouse and human cancers.
Which NIH institute is associated with this opportunity?
This funding announcement is associated with the National Cancer Institute (NCI) within the National Institutes of Health (NIH).
What grant mechanism is used for PAR-14-241?
The opportunity uses the NIH R01 Research Project Grant mechanism.
What is the maximum award amount listed for this opportunity?
The listed award ceiling in the provided source data is $450,000.
Is cost sharing or matching required?
No. The opportunity states that no cost sharing or matching is required.
When was PAR-14-241 posted, and when did it close?
It was posted on May 30, 2014. The original and final closing date listed is May 7, 2017.
Is this funding opportunity still active?
No. It was archived on June 7, 2017, meaning it is no longer active. It can still be useful as a reference for the types of model rigor and translational alignment NCI sought to encourage during that period.
What CFDA program areas are associated with this opportunity?
The cancer-related activities are aligned to CFDA program areas 93.393, 93.394, 93.395, and 93.396, spanning cancer cause and prevention, detection and diagnosis, treatment, and cancer biology.
Who is eligible to apply?
Eligibility is broad and includes many categories of organizations, including public and private institutions of higher education; nonprofits (including 501(c)(3) and certain non-501(c)(3) entities); for-profit organizations (including small businesses and other for-profits); and various levels of government (state, local, tribal, special districts, and housing authorities).
Are minority-serving and community-based institutions included in eligibility?
Yes. The FOA explicitly includes a wide range of institution types and communities, including HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and AANAPISI organizations, as well as faith-based and community-based organizations.
Are foreign organizations allowed to apply?
Yes. Non-U.S. entities (foreign organizations and foreign institutions) are eligible to apply. Non-U.S. components of U.S. organizations are eligible, and foreign components (as defined by NIH policy) are permitted.
Where can applicants find the official archived announcement?
The full archived announcement and official details are available on the NIH Grants Guide page: http://grants.nih.gov/grants/guide/pa-files/PAR-14-241.html
Who handled technical access questions related to the announcement?
Technical access questions were directed to the NIH Office of Extramural Research (OER) webmaster email listed in the source information.
Browse more opportunities from the same category: Education Health
Next opportunity: Office of Postsecondary Education (OPE) Foreign Language and Area Studies Fellowships Program CFDA Number 84.015B
Previous opportunity: Office of Postsecondary Education (OPE)National Resource Centers Program CFDA Number 84.015A
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 14 241
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 14 241) also looked into and applied for these:
| Funding Opportunity |
|---|
| Oncology Models Forum (U24) Apply for PAR 14 239 Funding Number: PAR 14 239 Agency: National Institutes of Health Category: Education Health Funding Amount: $750,000 |
| Limited Competition Biospecimen Banks to Support NCI Clinical Trials Network (NCTN) (U24) Apply for RFA CA 14 501 Funding Number: RFA CA 14 501 Agency: National Institutes of Health Category: Education Health Funding Amount: $11,750,000 |
| Molecular and Cellular Characterization of Screen Detected Lesions Coordinating Center and Data Management Group (U01) Apply for RFA CA 14 011 Funding Number: RFA CA 14 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Molecular and Cellular Characterization of Screen Detected Lesions (U01) Apply for RFA CA 14 010 Funding Number: RFA CA 14 010 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Innovation Corps (I Corps) Team Training Pilot Program for NIH Phase I Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Grantees (Admin Supp) Apply for PAR 14 261 Funding Number: PAR 14 261 Agency: National Institutes of Health Category: Education Health Funding Amount: $25,000 |
| Outstanding Investigator Award (R35) Apply for PAR 14 267 Funding Number: PAR 14 267 Agency: National Institutes of Health Category: Education Health Funding Amount: $600,000 |
| The National Drug Abuse Treatment Clinical Trials Network (UG1) Apply for RFA DA 15 008 Funding Number: RFA DA 15 008 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Connectomes Related to Human Disease (U01) Apply for PAR 14 281 Funding Number: PAR 14 281 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Extracellular Vesicles in HIV/AIDS and Substance Abuse (R01) Apply for RFA DA 15 011 Funding Number: RFA DA 15 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Extracellular Vesicles in HIV/AIDS and Substance Abuse (R21) Apply for RFA DA 15 012 Funding Number: RFA DA 15 012 Agency: National Institutes of Health Category: Education Health Funding Amount: $2,000,000 |
| Innovative Research in Cancer Nanotechnology (IRCN) (U01) Apply for PAR 14 285 Funding Number: PAR 14 285 Agency: National Institutes of Health Category: Education Health Funding Amount: $450,000 |
| Centers of Cancer Nanotechnology Excellence (CCNEs) (U54) Apply for RFA CA 14 013 Funding Number: RFA CA 14 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Interventions for Youth who Misuse/Abuse Prescription Stimulant Medications in High School and/or College Attending Youth (U01) Apply for RFA DA 15 010 Funding Number: RFA DA 15 010 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| Arts Based Approaches in Palliative Care for Symptom Management (R01) Apply for PAR 14 294 Funding Number: PAR 14 294 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Cancer Intervention and Surveillance Modeling Network (CISNET) (U01) Apply for RFA CA 14 012 Funding Number: RFA CA 14 012 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| New Approaches to Synthetic Lethality for Mutant KRas Dependent Cancers (U01) Apply for PAR 14 314 Funding Number: PAR 14 314 Agency: National Institutes of Health Category: Education Health Funding Amount: $750,000 |
| Obesity and Asthma Awareness and Self Management (R01) Apply for PA 14 316 Funding Number: PA 14 316 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Limited Competition AIDS Malignancy Clinical Trials Consortium (UM1) Apply for RFA CA 14 502 Funding Number: RFA CA 14 502 Agency: National Institutes of Health Category: Education Health Funding Amount: $21,400,000 |
| Developing Interventions for Health Enhancing Physical Activity (R21/R33) Apply for PAR 14 321 Funding Number: PAR 14 321 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Training Modules to Enhance Data Reproducibility (R25) Apply for RFA GM 15 006 Funding Number: RFA GM 15 006 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 14 241", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.